Effect of IL-1alpha on the expression of cartilage matrix proteins in human chondrosarcoma cell line OUMS-27.
We examined the effect of the inflammatory mediator interleukin-1alpha (IL-1alpha) on cell proliferation, alkaline phosphatase (ALPase) activity, and the expressions of cartilage matrix proteins, bone morphogenetic protein-2 (BMP-2), and BMP-2 receptors in human chondrosarcoma cell line OUMS-27 (chondrocytes). The cells were cultured with Dulbecco's modified Eagle's medium containing 15% fetal bovine serum with 0, 1, 10, or 100 units/ml of IL-1alpha for up to 14 days. The expressions of cartilage matrix proteins, BMP-2, and BMP-2 receptors were estimated by determining mRNA levels using semiquantitative or real-time PCR and/or by determining protein levels using Enzyme-linked immunosorbent assay. Cell proliferation was decreased after 5 days in culture with IL-1alpha. The ALPase activity was decreased significantly in the presence of IL-1alpha until day 10 of culture. The expression of type II collagen was significantly decreased after 7 days in culture with IL-1alpha. The expressions of aggrecan and link protein were significantly decreased through day 14 of culture with IL-1alpha. The expression of BMP-2 was increased at days 3, 7, and 14 of culture with IL-1alpha, while the expression of type II receptor for BMP-2 was significantly decreased in the samples. These results suggest that IL-1alpha suppresses the expression of cartilage matrix proteins through a suppression of the autocrine action of BMP-2, brought about by the decrease in BMP-2 receptor expression in chondrocytes.
Department of Crown and Bridge Prosthodontics, Nihon University School of Dentistry, Tokyo 101-8310, Japan.
Yukiko
Y
Aida
Masao
M
Maeno
Emi
E
Ito-Kato
Naoto
N
Suzuki
Hisaka
H
Shiratsuchi
Hideo
H
Matsumura
D000469:Alkaline Phosphatase / Q000378:metabolism; D052004:Bone Morphogenetic Protein Receptors; D019485:Bone Morphogenetic Proteins / Q000378:metabolism; D064236:Cartilage Oligomeric Matrix Protein; D049109:Cell Proliferation / Q000187:drug effects*; D024043:Collagen Type II / Q000378:metabolism; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects*; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D064235:Matrilin Proteins; D012333:RNA, Messenger / Q000378:metabolism*; D017978:Receptors, Growth Factor / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
D019485:Bone Morphogenetic Proteins; D064236:Cartilage Oligomeric Matrix Protein; D024043:Collagen Type II; D017931:DNA Primers; D016326:Extracellular Matrix Proteins; D006023:Glycoproteins; D007375:Interleukin-1; D064235:Matrilin Proteins; D012333:RNA, Messenger; D017978:Receptors, Growth Factor; C577553:TSP5 protein, human; D052004:Bone Morphogenetic Protein Receptors; D000469:Alkaline Phosphatase